366 related articles for article (PubMed ID: 37190280)
1. Gene Targets of CAR-T Cell Therapy for Glioblastoma.
Wang C; Li Y; Gu L; Chen R; Zhu H; Zhang X; Zhang Y; Feng S; Qiu S; Jian Z; Xiong X
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190280
[TBL] [Abstract][Full Text] [Related]
2. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
3. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Verma A; Rafiq S
Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
[TBL] [Abstract][Full Text] [Related]
5. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening.
Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R
J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight.
Land CA; Musich PR; Haydar D; Krenciute G; Xie Q
J Transl Med; 2020 Nov; 18(1):428. PubMed ID: 33176788
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
Kringel R; Lamszus K; Mohme M
Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma.
Maggs L; Cattaneo G; Dal AE; Moghaddam AS; Ferrone S
Front Neurosci; 2021; 15():662064. PubMed ID: 34113233
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
10. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma.
Liang T; Song Y; Gu L; Wang Y; Ma W
Int J Gen Med; 2023; 16():4121-4141. PubMed ID: 37720174
[TBL] [Abstract][Full Text] [Related]
11. Prospective approaches to enhancing CAR T cell therapy for glioblastoma.
Choi SI; Yin J
Front Immunol; 2022; 13():1008751. PubMed ID: 36275671
[TBL] [Abstract][Full Text] [Related]
12. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
[TBL] [Abstract][Full Text] [Related]
13. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
14. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
15. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression.
Luksik AS; Yazigi E; Shah P; Jackson CM
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900205
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
17. Targeting of the alpha
Cobb DA; de Rossi J; Liu L; An E; Lee DW
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210306
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
MartÃnez Bedoya D; Dutoit V; Migliorini D
Front Immunol; 2021; 12():640082. PubMed ID: 33746981
[TBL] [Abstract][Full Text] [Related]
19. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.
Li G; Zhang Z; Cai L; Tang X; Huang J; Yu L; Wang G; Zhong K; Cao Y; Liu C; Wang Y; Tong A; Zhou L
Oncoimmunology; 2021; 10(1):1983306. PubMed ID: 34595061
[TBL] [Abstract][Full Text] [Related]
20. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]